Total reported value
$1.4B
Reporting period: 2026-03-31 · Number of holdings: 12
Fairmount Funds Management LLC disclosed 12 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.4B and a quarterly turnover rate of 72.5%.
Trim APGE
-85.4% -$129.5M
Trim COGT
-38.9% -$108.0M
Add DNTH
+18.7% $124.8M
Add SYRE
0.0% $71.0M
Add ORKA
0.0% $69.4M
Trim VRDN
0.0% -$45.3M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DMRA | Damora Therapeutics INC | Stock-Other | 16.30% | +16.30% | NEW | |
| 2 | DNTH | Dianthus Therapeutics INC | Stock-Other | 15.38% | +8.68% | +18.72% | |
| 3 | COGT | Cogent Biosciences INC | Stock-Other | 15.30% | -9.04% | -38.87% | |
| 4 | SYRE | Spyre Therapeutics INC | Stock-Other | 14.64% | +4.62% | — | |
| 5 | ORKA | Oruka Therapeutics INC | Stock-Other | 13.13% | +4.58% | — | |
| 6 | VRDN | Viridian Therapeutics INC | Stock-Other | 5.53% | -3.74% | — | |
| 7 | ELVN | Enliven Therapeutics INC | Stock-Other | 5.25% | +0.90% | -50.00% | |
| 8 | JBIO | Jade Biosciences INC | Stock-Other | 4.62% | -0.73% | — | |
| 9 | ✓ | Crescent Biopharma INC. | Stock-Other | 3.65% | +1.17% | — | |
| 10 | ZBIO | Zenas Biopharma INC | Stock-Other | 3.33% | -2.78% | +6.79% | |
| 11 | APGE | Apogee Therapeutics INC | Stock-Other | 1.82% | -9.95% | -85.42% | |
| 12 | IKT | Inhibikase Therapeutics INC | Stock-Other | 1.05% | -0.30% | — |
Performance for Q3 2026
+21.6%
Performance Last 4 Quarters
+190%
Based on 66% of reported portfolio value with available pricing
Not enough sector-mapped data yet
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 12 | $1.4B | 73 | |
| 2025-12-31 | 13 | $1.3B | 71 | |
| 2025-09-30 | 17 | $1.1B | 52 | |
| 2025-06-30 | 17 | $771.9M | 0 | |
| 2025-03-31 | 15 | $644.6M | 100 | |
| 2024-12-31 | 17 | $1.0B | 0 | |
| 2024-09-30 | 15 | $1.2B | 0 | |
| 2024-06-30 | 13 | $885.1M | 0 | |
| 2024-03-31 | 15 | $917.4M | 0 | |
| 2023-12-31 | 16 | $946.5M | 0 | |
| 2023-09-30 | 20 | $831.2M | 0 | |
| 2023-06-30 | 17 | $709.3M | 0 | |
| 2023-03-31 | 16 | $581.5M | 0 | |
| 2022-12-31 | 16 | $630.4M | 0 | |
| 2022-09-30 | 27 | $568.9M | 0 | |
| 2022-06-30 | 27 | $436.9M | 0 | |
| 2022-03-31 | 22 | $422.9M | 0 | |
| 2021-12-31 | 20 | $303.3M | 0 | |
| 2021-09-30 | 20 | $275.0M | 0 | |
| 2021-06-30 | 19 | $243.2M | 99 | |
| 2021-03-31 | 21 | $237.2M | 44 | |
| 2020-12-31 | 18 | $279.6M | 38 | |
| 2020-09-30 | 17 | $236.1M | 31 | |
| 2020-06-30 | 14 | $224.2M | 31 | |
| 2020-03-31 | 14 | $164.9M | 50 | |
| 2019-12-31 | 15 | $165.0M | 0 |
Fairmount Funds Management LLC's most significant position changes for 2026-03-31: New buy: Damora Therapeutics INC (DMRA); Sold out: Nuvalent Inc-a (NUVL); Sold out: Kiniksa Pharmaceuticals International, plc (KNSA); Trim: Apogee Therapeutics INC (APGE) — shares -85.42%; Trim: Cogent Biosciences INC (COGT) — shares -38.87%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics INC | +8.7% | +18.72% | Add |
| 2 | SYRE | Spyre Therapeutics INC | +4.6% | — | Unchanged |
| 3 | ORKA | Oruka Therapeutics INC | +4.6% | — | Unchanged |
| 4 | ✓ | Crescent Biopharma INC. | +1.2% | — | Unchanged |
| 5 | ELVN | Enliven Therapeutics INC | +0.9% | -50.00% | Trim |
| 6 | IKT | Inhibikase Therapeutics INC | -0.3% | — | Unchanged |
| 7 | JBIO | Jade Biosciences INC | -0.7% | — | Unchanged |
| 8 | ZBIO | Zenas Biopharma INC | -2.8% | +6.79% | Add |
| 9 | VRDN | Viridian Therapeutics INC | -3.7% | — | Unchanged |
| 10 | COGT | Cogent Biosciences INC | -9% | -38.87% | Trim |
| 11 | APGE | Apogee Therapeutics INC | -10% | -85.42% | Trim |
| 12 | DMRA | Damora Therapeutics INC | — | NEW | New buy |
| 13 | NUVL | Nuvalent Inc-a | — | EXIT | Sold out |
| 14 | KNSA | Kiniksa Pharmaceuticals International, plc | — | EXIT | Sold out |